Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain

Core Insights - Vaccinex has reported positive results from its SIGNAL-AD Phase 1b/2 trial of pepinemab in early stages of Alzheimer's disease, focusing on its potential to intervene early and block astrocyte activation and inflammation [2][3][7] Group 1: Clinical Findings - The study demonstrated that pepinemab treatment inhibits the increase of plasma GFAP and p-tau 217 biomarkers during Mild Cognitive Impairment (MCI), which is the earliest stage of Alzheimer's disease [3][4] - Pepinemab treatment may slow cognitive decline in patients progressing to mild dementia, as indicated by strong treatment trends across various cognitive measures [3][4] - A proteomic analysis of cerebrospinal fluid showed that several proteins associated with normal Alzheimer's progression were inhibited by pepinemab treatment, supporting its potential benefits [4] Group 2: Mechanism of Action - Pepinemab has been shown to inhibit or reverse damage caused by toxic aggregates of alpha synuclein, which are linked to various neurodegenerative diseases, including Alzheimer's [5][7] - The company plans to focus on treating patients with MCI or mild dementia due to Alzheimer's with pepinemab to slow disease progression [7] Group 3: Future Development - Vaccinex aims to continue discussions for partnerships to further develop pepinemab for Alzheimer's, Huntington's disease, and potentially other neurodegenerative diseases [7]